Abstract
The formation of senile plaques containing amyloid β peptides (Aβ peptides) as a major constituent plays a significant role in development of Alzheimers disease. The concentration of Aβ peptides in the brain is determined by a combination of their rate of synthesis and their rate of clearance. Considerable effort has been expended in producing inhibitors of the β and γ secretases involved in the synthesis of the Aβ peptides. More recently interest in the mechanism of clearance of the Aβ peptides has emerged, as promoting Aβ peptide clearance represents an alternative therapeutic approach. It now appears that cleavage of Aβ peptide by peptidases and proteases represents the major mechanism of clearance. This review describes those peptidases and proteases implicated in Aβ peptide clearance, the evidence that these enzymes function in vivo, and how they may represent new therapeutic targets.
Keywords: amyloid beta-peptide, ab, a betapeptides, b secretase, r secretase
Current Pharmaceutical Design
Title: Peptidases, Proteases and Amyloid β-Peptide Catabolism
Volume: 9 Issue: 6
Author(s): Louis B. Hersh
Affiliation:
Keywords: amyloid beta-peptide, ab, a betapeptides, b secretase, r secretase
Abstract: The formation of senile plaques containing amyloid β peptides (Aβ peptides) as a major constituent plays a significant role in development of Alzheimers disease. The concentration of Aβ peptides in the brain is determined by a combination of their rate of synthesis and their rate of clearance. Considerable effort has been expended in producing inhibitors of the β and γ secretases involved in the synthesis of the Aβ peptides. More recently interest in the mechanism of clearance of the Aβ peptides has emerged, as promoting Aβ peptide clearance represents an alternative therapeutic approach. It now appears that cleavage of Aβ peptide by peptidases and proteases represents the major mechanism of clearance. This review describes those peptidases and proteases implicated in Aβ peptide clearance, the evidence that these enzymes function in vivo, and how they may represent new therapeutic targets.
Export Options
About this article
Cite this article as:
Hersh B. Louis, Peptidases, Proteases and Amyloid β-Peptide Catabolism, Current Pharmaceutical Design 2003; 9 (6) . https://dx.doi.org/10.2174/1381612033391676
DOI https://dx.doi.org/10.2174/1381612033391676 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Zebrafish: Predictive Model for Targeted Cancer Therapeutics from Nature
Current Cancer Drug Targets Discovery and Development of Endocannabinoid-Hydrolyzing Enzyme Inhibitors
Current Topics in Medicinal Chemistry Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design
Current Neuropharmacology A Speech Recognition-based Solution for the Automatic Detection of Mild Cognitive Impairment from Spontaneous Speech
Current Alzheimer Research Patent Selections
Recent Patents on Drug Delivery & Formulation Polyploidy: The Link Between Senescence and Cancer
Current Pharmaceutical Design Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Neuronal and Extraneuronal Nicotinic Acetylcholine Receptors
Current Neuropharmacology Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Current Pharmacological Interventions in Panic Disorder
CNS & Neurological Disorders - Drug Targets Venous Collateral Circulation of the Extracranial Cerebrospinal Outflow Routes
Current Neurovascular Research Classifying Cognitive Normal and Early Mild Cognitive Impairment of Alzheimer’s Disease by Applying Restricted Boltzmann Machine to fMRI Data
Current Bioinformatics Cortisol Regulation in Patients with Type 2 Diabetes and the Metabolic Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Graphical Abstracts
Current Neuropharmacology <i>Nigella Sativa</i> (Black Seeds), A Potential Herb for the Pharmacotherapeutic Management of Hypertension - A Review
Current Cardiology Reviews Inflammatory Mediators in Smoke Inhalation Injury
Inflammation & Allergy - Drug Targets (Discontinued) Erythropoietin Requires NF-κB and its Nuclear Translocation to Prevent Early and Late Apoptotic Neuronal Injury During β-Amyloid Toxicity
Current Neurovascular Research The proNGF-p75NTR-Sortilin Signalling Complex as New Target for the Therapeutic Treatment of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Transitional Age Youth with Serious Mental Illness: High Acuity Patients Requiring Developmentally Informed Care in the Inpatient Hospital Setting
Adolescent Psychiatry Delta Opioid Peptides Derived from Plant Proteins
Current Pharmaceutical Design